Sanmartino Florencia, Cano-Cano Fátima, Rashid-López Raúl, Cruz-Gómez Álvaro Javier, Lozano-Soto Elena, Macías-García Paloma, Sánchez-Fernández Francisco L, López-Sosa Fernando, Gómez-Jaramillo Laura, Riqué-Dormido Jesús, Escamilla-Sevilla Francisco, Espinosa-Rosso Raúl, González-Rosa Javier J
Institute of Biomedical Research Cadiz (INiBICA), Cadiz, Spain.
University of Cadiz, Cadiz, Spain.
NPJ Parkinsons Dis. 2024 Oct 24;10(1):197. doi: 10.1038/s41531-024-00808-w.
The ability of serum biomarkers to predict the prognosis and response to deep-brain stimulation (DBS) therapy in Parkinson's disease (PD) patients is promising. Here, we showed that NfL differed between healthy individuals and PD patients and that changes in NfL, GFAP, and BDNF occurred only transiently after DBS surgery. Therefore, subthalamic stimulation does not promote neurodegeneration, and these biomarkers do not serve as clinical improvement endpoints in PD DBS patients.
血清生物标志物预测帕金森病（PD）患者预后及对深部脑刺激（DBS）治疗反应的能力很有前景。在此，我们表明健康个体与PD患者之间的神经丝轻链（NfL）存在差异，且NfL、胶质纤维酸性蛋白（GFAP）和脑源性神经营养因子（BDNF）仅在DBS手术后短暂出现变化。因此，丘脑底核刺激不会促进神经退行性变，并且这些生物标志物不能作为PD-DBS患者临床改善的终点指标。
